Needham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)

Category: Finance

Blueprint Medicines has received a 'buy' rating from Needham & Company with a price target of $130.00, indicating a potential upside of 29.62%. Other analysts have set various price targets, with an average target of $118.33. The company's stock has seen significant trading activity and has a market capitalization of $6.28 billion. Blueprint Medicines reported earnings of ($1.32) per share, beating estimates, and had revenue of $96.12 million for the last quarter. Insiders have sold a total of 130,064 shares in the last 90 days.

Keywords: Blueprint Medicines, stock analysis, investment ratings

Source: MarketBeat

Update At: 8/5/2024

Related Sources